AnaptysBio, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and commercializing transformative antibody-based therapeutic products for inflammatory diseases. The company leverages its proprietary somatic hypermutation (SHM)-based antibody discovery technology platform to generate a pipeline of novel antibodies. AnaptysBio's strategy centers on targeting well-validated biological pathways in new ways to address significant unmet medical needs in autoimmune and inflammatory conditions.
The headquarters serves as the primary center for AnaptysBio's research and development activities, clinical operations, corporate strategy, and administrative functions.
The facility includes specialized laboratory spaces essential for antibody discovery and development, alongside modern office environments. It is located in the Sorrento Valley area, known for its high concentration of biotech and technology companies.
AnaptysBio cultivates a work environment driven by scientific excellence, innovation, collaboration, and a strong commitment to developing therapies that can improve patients' lives.
The San Diego headquarters provides AnaptysBio with access to a rich ecosystem of scientific talent, research institutions, and capital, crucial for a biotechnology company focused on cutting-edge therapeutic development.
AnaptysBio's primary operational base and headquarters are located in the United States. While the company does not maintain a widespread network of international offices, its clinical trials are often conducted globally, involving research sites and patient populations in various countries to support its drug development programs. Future commercialization efforts for its product candidates would also likely target key international markets.
10421 Pacific Center Court, Suite 200
San Diego
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AnaptysBio' leadership includes:
AnaptysBio has been backed by several prominent investors over the years, including:
AnaptysBio has undergone key leadership changes in the past 12-18 months, including the appointment of a new President & CEO and a new CFO to guide its strategic objectives.
Discover the tools AnaptysBio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
AnaptysBio, Inc. most likely uses a common corporate email format structure. Based on patterns observed for companies of similar size and industry, the predominant format is often the first initial of the first name followed by the last name.
flast@anaptysbio.com
Format
dfaga@anaptysbio.com
Example
80%
Success rate
GlobeNewswire • February 27, 2024
AnaptysBio announced its Q4 and full-year 2023 financial results, along with updates on its clinical pipeline, including progress on rosnilimab (anti-PD-1 agonist) and ANB032 (anti-BTLA modulator) programs....more
GlobeNewswire • January 4, 2024
The company reported the dosing of the first patient in its AZURE Phase 2b clinical trial, evaluating rosnilimab for the treatment of moderate-to-severe atopic dermatitis....more
GlobeNewswire • November 1, 2023
AnaptysBio appointed Dennis Mulroy as its new Chief Financial Officer, bringing significant financial and operational leadership experience within the biotechnology sector....more
GlobeNewswire • August 2, 2023
AnaptysBio announced the appointment of Daniel Faga as its President and Chief Executive Officer, and as a member of the Board of Directors, succeeding Hamza Suria....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AnaptysBio, are just a search away.